Pegaspargase

證據等級: L5

預測適應症: 10 個

Pegaspargase: From Acute Lymphoblastic Leukemia to Precursor Lymphoblastic Lymphoma/Leukemia

One-Sentence Summary

Pegaspargase is a PEGylated asparaginase enzyme long used as a backbone agent in the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). The TxGNN model's top-ranked prediction — Precursor Lymphoblastic Lymphoma/Leukemia — is, in reality, a restatement of the drug's already-established core indication rather than a genuinely novel use. This signal is supported by 60+ clinical trials (many Phase 3) and 20 publications, but the evidence confirms known pharmacology rather than opening a new therapeutic direction. Several lower-ranked, more genuinely "new" candidates (e.g., Hodgkin lymphoma, lymphoid neoplasm broadly) carry much weaker and partly mismatched evidence and are flagged separately below.

Quick Overview

Item	Content
Original Indication	Acute Lymphoblastic Leukemia (ALL) / Lymphoblastic Lymphoma — internationally established use; not documented in German license data (drug not marketed)
Predicted New Indication	Precursor Lymphoblastic Lymphoma/Leukemia (essentially overlaps with the original approved use — see caveat below)
TxGNN Prediction Score	99.96%
Evidence Level	L1
Germany Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

⚠️ Important caveat: "Precursor lymphoblastic lymphoma/leukemia" is clinically synonymous with the drug's existing core indication (ALL/LBL), not a new disease area. The repurposing rationale in the evidence pack explicitly confirms this is "an existing approved mechanism, not a new use." Guardrails here concern management of known toxicities (hypersensitivity, pancreatitis, thrombosis), not de-novo indication risk.

Why is This Prediction Reasonable?

Currently, detailed structured mechanism-of-action data is not available from DrugBank in this evidence pack (marked as a Data Gap). Based on the accompanying repurposing rationale and known pharmacology, pegaspargase hydrolyzes circulating asparagine. Lymphoblasts in ALL/LBL characteristically have low or absent asparagine synthetase expression, making them dependent on exogenous asparagine; depleting it starves these cells and drives apoptosis. This is a textbook, decades-established mechanism — not a newly discovered pathway.

Because the top-ranked TxGNN prediction (precursor lymphoblastic lymphoma/leukemia) and the 5th-ranked prediction (acute lymphoblastic leukemia) both describe the drug's own approved indication, the model is essentially reproducing known biology rather than surfacing a repurposing opportunity. This is a useful sanity check on model validity but should not be reported to stakeholders as a "new indication."

The more interesting signals sit further down the ranked list — Hodgkin lymphoma (rank 8) and the broader "lymphoid neoplasm" category (rank 7) — where evidence is thinner and, on closer inspection, largely derived from a different disease entity (extranodal NK/T-cell lymphoma, a non-Hodgkin subtype) rather than classical Hodgkin lymphoma itself. This mismatch is explicitly called out in the rationale text and should be resolved before any further evaluation.

Clinical Trial Evidence

(from predicted_indications[0]: precursor lymphoblastic lymphoma/leukemia)

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03020030	Phase 3	Active, not recruiting	560	Large pediatric/adolescent newly-diagnosed ALL protocol with pegaspargase as backbone (Grade A relevance)
NCT02716233	Phase 3	Active, not recruiting	2044	French national pediatric ALL protocol optimizing L-asparaginase (pegaspargase) dosing/use (Grade A relevance)
NCT04954326	Phase 2	Completed	89	PK comparison of liquid vs lyophilized pegaspargase (S95014) formulations in newly diagnosed pediatric ALL
NCT06195735	N/A	Completed	649	Large observational study forecasting hypersensitivity to PEG-asparaginase to optimize ALL outcomes
NCT05602194	Phase 3	Recruiting	440	Randomized trial of levocarnitine to prevent asparaginase-associated hepatotoxicity in AYA ALL/LBL patients
NCT00187083	Phase 3	Completed	40	Native vs PEG-asparaginase comparison during induction for relapsed/refractory childhood ALL
NCT00003437	Phase 3	Unknown	1800	UK national childhood ALL trial comparing steroid/chemotherapy regimens
NCT01665001	Phase 2	Unknown	200	Individualized MRD-adapted therapy for adults with precursor lymphoid neoplasms (PALG)
NCT00905034	Phase 2	Completed	37	Methotrexate/vincristine/pegylated-asparaginase/dexamethasone salvage regimen in relapsed ALL
NCT00882206	Phase 2	Terminated	15	Decitabine + vorinostat + VPLD chemo (incl. PEG-asparaginase) in relapsed/refractory ALL/LBL

Literature Evidence

PMID	Year	Type	Journal	Key Findings
37276451	2023	Cohort (Tier 1)	Blood Advances	GIMEMA LAL1913: pegaspargase-modified risk-oriented program improves outcomes in adult ALL/LBL
34228505	2021	Cohort (Tier 1)	J Clin Oncol	DFCI 11-001: efficacy/toxicity of pegaspargase vs calaspargase pegol in childhood ALL
40109190	2025	Review (Tier 2)	Haematologica	Expert consensus on recognition/prevention/management of asparaginase-associated adverse events in adults
40163215	2025	Cohort/Phase 2	Int J Hematol	Phase 2 multicenter study of pegaspargase in Japanese patients with untreated ALL
35271306	2022	Phase 3 RCT	J Clin Oncol	COG AALL1231: bortezomib in newly diagnosed T-ALL/T-LL (pegaspargase as backbone)
32813610	2020	Phase 3 RCT	J Clin Oncol	COG AALL0434: nelarabine in newly diagnosed T-ALL (pegaspargase-containing backbone)
39322712	2024	Phase 2 (long-term f/u)	Leukemia	Venetoclax + hyper-CVAD/nelarabine/pegylated asparaginase in T-ALL/LBL
35987855	2022	Consensus/Review	Bulletin du Cancer	French Society recommendations for prevention/management of pegaspargase toxicities
31571395	2020	Case series	Pediatr Blood Cancer	Rapid desensitization protocol allowing continued pegaspargase use in hypersensitive pediatric patients
17696798	2007	Review	Expert Opin Pharmacother	Foundational pharmacology review of PEG-asparaginase in leukemia treatment

Other TxGNN-Predicted Indications (Full Candidate List)

This evidence pack scored 10 candidate indications for pegaspargase. For transparency, given the multi-candidate nature of this pack, the full ranking is summarized below:

Rank	Disease	Score	Evidence Level	Recommendation	Note
1	Precursor lymphoblastic lymphoma/leukemia	99.96%	L1	Proceed with Guardrails	= existing approved indication, not novel
2	Pre-germinal center CLL/SLL	99.95%	L5	Hold	No mechanistic support; likely graph-structure artifact
3	CLL/SLL with IGHV somatic hypermutation	99.95%	L5	Hold	Same as above
4	Follicular lymphoma	99.90%	L5	Hold	Mature B-cells; not asparagine-dependent; no evidence
5	Acute lymphoblastic leukemia	99.89%	L1	Proceed with Guardrails	= existing approved indication, not novel
6	Methylcobalamin deficiency (cblE)	99.74%	L5	Hold	Mechanistically unrelated; likely data/ontology noise
7	Lymphoid neoplasm (broad category)	99.71%	L3	Research Question	Evidence is ALL-specific, not generalizable to all lymphoid tumors
8	Hodgkin lymphoma	99.71%	L2	Research Question	⚠️ Most cited evidence is actually for NK/T-cell lymphoma (a different NHL subtype), not classical Hodgkin lymphoma — label mismatch needs resolution
9	CLL/SLL	99.68%	L5	Hold	No mechanistic support; no evidence
10	CML blast phase, BCR-ABL1+	99.61%	L4	Research Question	Plausible only for lymphoid blast crisis subtype; not distinguished from myeloid blast crisis in evidence

Interpretation: Only ranks 1 and 5 have strong (L1) evidence, and both simply restate the known indication. Ranks 7, 8, and 10 are genuine "Research Question" candidates but have weak, partially mismatched evidence. Ranks 2, 3, 4, 6, and 9 should be held — no plausible mechanism and zero supporting trials/literature.

Germany Market Information

Pegaspargase currently has no marketing authorization in Germany in this dataset (market_status: 未上市, total_licenses: 0). No product listings are available to summarize.

Cytotoxicity

Pegaspargase is an antineoplastic agent (asparagine-depleting enzyme), used as a core component of ALL/LBL chemotherapy regimens — it meets the antineoplastic criteria via original indication and established drug class.

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — enzyme-based (asparagine-depleting), distinct from DNA-damaging or targeted agents
Myelosuppression Risk	Low direct myelosuppression from pegaspargase itself; however, it is almost always combined with myelosuppressive agents (vincristine, anthracyclines, corticosteroids), so combination-regimen myelosuppression risk is high
Emetogenicity Classification	Low to moderate
Monitoring Items	Coagulation panel (fibrinogen, antithrombin III), liver function tests, lipase/amylase (pancreatitis), fasting glucose/triglycerides, signs of hypersensitivity, CBC (regimen-wide)
Handling Protection	Yes — standard cytotoxic/antineoplastic drug handling precautions apply during preparation and administration

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and DDI data are all marked as data gaps in this evidence pack; no DDI records were found.)

Conclusion and Next Steps

Decision: Proceed with Guardrails (for the top-ranked candidate — with the caveat that this is confirmatory, not a new indication)

Rationale:

The top TxGNN prediction restates pegaspargase's already-established, guideline-standard use in ALL/LBL, backed by multiple Phase 3 trials and consistent literature — evidence is strong, but there is no new indication value to capture here.
Genuinely exploratory candidates (Hodgkin lymphoma, lymphoid neoplasm broadly, CML lymphoid blast crisis) remain at the "Research Question" stage with thin or mismatched evidence and should not proceed further without additional work.

To proceed, the following is needed:

Resolve DG001 (Blocking): obtain TFDA/BfArM package insert warnings and contraindications before any S1 safety pre-assessment can proceed.
Resolve DG002 (High): obtain structured MOA data from DrugBank to support formal mechanistic-link scoring.
For the Hodgkin lymphoma candidate (rank 8): clarify whether the underlying evidence (NK/T-cell lymphoma trials) was mis-mapped to Hodgkin lymphoma before any further evaluation.
For "lymphoid neoplasm" (rank 7): narrow the evidence base to disease subtypes with actual asparagine-synthetase-deficiency data, rather than treating it as a single broad category.
Given the drug is not marketed in Germany, confirm regulatory pathway/relevance before allocating further evaluation resources to this market.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.